Webinars and Sponsored Roundtables — Register Now

Tuesday, July 21, 2026, 11:00-11:30 AM CT

Learning Objectives:
  • Explain how transparency and manufacturer partnerships improve quality, consistency, and decision-making confidence in specimen management.
  • Evaluate blood collection tubes beyond cost and commodity assumptions, incorporating clinical impact and risk into decision-making.
  • Assess the potential risk points when using a blood collection device that has not been cleared for a specific purpose.

Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

December 2024

Anatomic pathology selected abstracts

December 2024—Recurrence of Crohn’s disease within one or two years of resection is common. The authors conducted a study in which they sought to identify histologic features in Crohn’s disease resections that may predict earlier recurrence (18 months or less) to potentially guide postoperative management. They performed a single-institution, retrospective database review of 41 patients who had first-time Crohn’s disease bowel resection specimens collected between October 2002 and December 2007. Patient demographics and Crohn’s disease course were documented. Slides were reviewed for the distribution and composition of inflammation, small bowel pyloric metaplasia, and the presence and characteristics of submucosal fibrosis and granulomas.

Molecular pathology selected abstracts

December 2024—Acute promyelocytic leukemia is generally characterized by presence of the PML::RARA fusion. However, a subset of cases with morphological, cytochemical, and immunophenotypic features of acute promyelocytic leukemia (APL) lack this canonical fusion gene and instead present with alternate fusions. These include RARA fusions with partners other than PML and fusions involving other retinoic acid receptor (RAR) genes, such as RARG. Leukemias with these variant fusions often resist all-trans retinoic acid (ATRA) therapy. Specifically, the ATRA sensitivity of RARA fusion genes varies based on its 5′ fusion partner. Interestingly, in some studies, the artificially induced variant RAR bipartite fusion genes responded well to ATRA.

Newsbytes

December 2024—In a casual water cooler conversation, while standing around a coagulation analyzer to be precise, Lisa Daniel listened to her laboratory colleagues and a hospitalist, who happened to stop by the department, discuss their frustration with duplicate and other unnecessary tests. This led her to start a small committee, which in eight years has sextupled in size and undertaken numerous cost-saving measures.

Q&A column

December 2024
Q. What are the preferred tests for chronic kidney disease (CKD) screening and classification? Read answer.
Q. Is there a formula to correct a white blood cell count for micromegakaryocytes, or are megakaryocytes considered clinically insignificant unless there are greater than five per 100 WBCs? Is there a movement to drop reporting percents for individual WBCs, reactive lymphocytes, and reticulocytes? If so, does the CAP support such a change? Read answer.

Put It on the Board

December 2024—In a white paper released this fall, the CAP sets forth five recommendations to address private health insurers’ interference in patient-physician and physician-physician relationships by limiting the number of in-network physicians or exclusively contracting with particular providers and facilities. In the paper, “Examining the State of Health Care’s Private Payers and the Adverse Impact of Insurance Interference,” the CAP says “Two-thirds of the country’s population is covered by private health insurance, yet the coverage provided is less and less meaningful.”